Scandion Oncology A/S

OM:SCOL Stock Report

Market Cap: SEK 2.6m

Scandion Oncology Management

Management criteria checks 2/4

Scandion Oncology's CEO is Francois Martelet, appointed in Jan 2023, has a tenure of 2.17 years. directly owns 0.005% of the company’s shares, worth SEK122.92. The average tenure of the management team and the board of directors is 2.7 years and 3.5 years respectively.

Key information

Francois Martelet

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.2yrs
CEO ownership0.005%
Management average tenure2.7yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Aug 02
We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully

Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Feb 01
Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

May 26
Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation

We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

Jan 06
We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely

CEO

Francois Martelet (64 yo)

2.2yrs

Tenure

Dr. Francois Regis Martelet, M.D., is a Non-executive Director of Novigenix SA since June 2019. He had been the Chief Executive Officer of Vivesto AB (formerly known as Oasmia Pharmaceutical AB (publ)) sin...

Leadership Team

NamePositionTenureCompensationOwnership
Jan Stenvang
Chief Scientific Officer2.2yrsno data0.58%
SEK 14.9k
Francois Martelet
Chief Executive Officer2.2yrsno data0.0048%
SEK 122.9
Johnny Stilou
Chief Financial Officer3.6yrsno data0.0057%
SEK 146.7
Morten Nissen
General Counselno datano datano data
Mads Kronborg
Head of External Communication3.2yrsno datano data

2.7yrs

Average Tenure

Experienced Management: SCOL's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Palle Christophersen
Member of Scientific Advisory Boardno datano datano data
Richard Schilsky
Member of Clinical Advisory Board3.9yrsno datano data
Alejandra Maria Cristina Mork
Independent Deputy Chairman of the Board2.9yrsno datano data
Eric Cutsem
Member of Clinical Advisory Board3.5yrsno datano data
Josep Tabernero Caturla
Member of Clinical Advisory Board3.5yrsno datano data
Susan Bates
Member of Scientific Advisory Boardno datano datano data
Keld Jorgensen
Independent Director2.9yrsno datano data
Thomas T. Seufferlein
Member of Clinical Advisory Board3.5yrsno datano data
Martin Moller
Independent Chairman of the Board3.8yrsno data0.0027%
SEK 68.9
Michel Ducreux
Member of Clinical Advisory Boardless than a yearno datano data
Per Pfeiffer
Independent Director1.2yrsno datano data

3.5yrs

Average Tenure

63yo

Average Age

Experienced Board: SCOL's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 10:40
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scandion Oncology A/S is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo RomanoffEdison Investment Research
Christian BinderRedeye